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Author Correction: Surgical Standards for Management of the
Axilla in Breast Cancer Clinical Trials with Pathological
Complete Response Endpoint
Judy C. Boughey1, Michael D. Alvarado2, Rachael B. Lancaster3, W. Fraser Symmans4, Rita Mukhtar2, Jasmine M. Wong2,
Cheryl A. Ewing2, David A. Potter5, Todd M. Tuttle6, Tina J. Hieken1, Jodi M. Carter7, James W. Jakub1, Henry G. Kaplan8,
Claire L. Buchanan8, Nora T. Jaskowiak9, Husain A. Sattar10, Jeffrey Mueller10, Rita Nanda11, Claudine J. Isaacs12, Paula R. Pohlmann12,
Filipa Lynce12, Eleni A. Tousimis12, Jay C. Zeck12, M. Catherine Lee13, Julie E. Lang14, Paulette Mhawech-Fauceglia14, Roshni Rao15,
Bret Taback15, Constantine Goodellas16, Margaret Chen15, Kevin M. Kalinsky15, Hanina Hibshoosh15, Brigid Killelea17, Tara Sanft17,
Gillian L. Hirst2, Smita Asare18, Jeffrey B. Matthews2, Jane Perlmutter19, Laura J. Esserman2 and I-SPY2 Investigators25
npj Breast Cancer             (2019) 5:2 ; https://doi.org/10.1038/s41523-018-0096-0
Correction to: npj Breast Cancer 4, 26 (2018) https://doi.org/
10.1038/s41523-018-0074-6; Article Published online 17 August
2018
In the original version of the published article, Constantine
Godellas was mistakenly omitted from the Author list and Author
Contributions statement. Constantine Godellas has been added as
the 29th Author, and is affiliated with Loyola University Medical
Center, Maywood, IL, United States. The author contributions
statement has been updated as follows: Author Contributions
Statement: Judy C. Boughey conducted the review of current
protocols, led the effort to establish new I-SPY standards and was
the principal author of the manuscript. Laura Esserman co-led the
review and standardization processes. Michael D. Alvarado,
Rachael B. Lancaster, Fraser Symmans, W, Rita Mukhtar, Jasmine
Wong, Cheryl Ewing, David Potter, Todd Tuttle, Tina Hieken, Jodi
Carter, James Jakub, Henry Kaplan, Claire Buchanan, Nora
Jaskowiak, Husain Sattar, Jeffrey Mueller, Rita Nanda, Claudine
Isaacs, Paula Pohlmann, Filipa Lynce, Eleni Tousimis, Jay Zeck, M.
Catherine Lee, Julie Lang, Paulette Mhawech-Fauceglia, Roshni
Rao, Bret Taback, Margaret Chen, Kevin Kalinsky, Hanina
Hibshoosh, Brigid Killelea, Constantine Godellas, and Tara Sanft
provided medical and scientific expertise/opinion towards the
development of I-SPY standards. Jane Perlmutter provided the
patient advocate’s perspective in these discussions. All I-SPY2 trial
investigators participated in the review of current standards, had
the opportunity to participate in and comment on proposed
standards and the final manuscript. Gill Hirst and Smita Asare
provided expertise on, conducted and analyzed surveys of I-SPY
trial sites. Jeffrey B. Matthews provided significant input and
editing throughout the manuscript development process. All
authors reviewed manuscript drafts and signed off on the final
manuscript. This has been corrected in the HTML and PDF version
of the article.
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